Literature DB >> 9951096

[Repeat surgery for thyroid nodules (excluding cancer and hyperthyroidism)].

M Makeieff1, P Rubinstein, B Youssef, L Crampette, B Guerrier.   

Abstract

Second procedures for recurrent thyroid disease are known to carry a high risk of iatrogenic damage, particularly to the inferior laryngeal nerves and parathyroid glands. This risk has been clearly evaluated for the primary procedure, but is less clearly for second procedures. A series of 117 patients with solitary or multiple cold thyroid nodules were evaluated (excluding those patients re-operated for recurrent thyroid carcinoma or goitre associated with hyperthyroidism) to determine the operative risks. The level of transient and permanent recurrent laryngeal nerve palsy was 2.56% and 1.7% respectively. The level of transient and permanent hypocalcaemia was 12.9% and 4.62% respectively. The frequency of re-operation for recurrent disease involving the pyramidal lobe following total thyroidectomy (6 cases) highlights the importance of removing it during the primary procedure. The number of cases of cancer discovered at re-operation was 4.3% (5 cases out of 117).

Entities:  

Mesh:

Year:  1998        PMID: 9951096

Source DB:  PubMed          Journal:  Ann Chir        ISSN: 0003-3944


  3 in total

1.  Intraoperative neuromonitoring does not reduce the incidence of recurrent laryngeal nerve palsy in thyroid reoperations: results of a retrospective comparative analysis.

Authors:  Piero F Alesina; Thomas Rolfs; Silvia Hommeltenberg; Jakob Hinrichs; Beate Meier; Wazma Mohmand; Sebastian Hofmeister; Martin K Walz
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

Review 2.  Intermittent neural monitoring of the recurrent laryngeal nerve in surgery for recurrent goiter.

Authors:  Beata Wojtczak; Marcin Barczyński
Journal:  Gland Surg       Date:  2016-10

Review 3.  Treatment and prevention of recurrence of multinodular goiter: an evidence-based review of the literature.

Authors:  Jacob Moalem; Insoo Suh; Quan-Yang Duh
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.